Modeling the impact of comorbidity on breast cancer patient outcomes.

Health Care Manag Sci

Edward P. Fitts Department of Industrial and Systems Engineering, North Carolina State University, Campus Box 7906, Raleigh, NC 27695-7906, USA.

Published: June 2010

The objective of this paper is to model the impact of comorbidity on breast cancer patient outcomes (e.g., length of stay and disposition). Previous studies suggest that comorbidities may significantly affect mortality risks for breast cancer patients. The 2006 AHRQ Nationwide Inpatient Sample (NIS) is used to analyze the relationships among comorbidities (e.g., hypertension, diabetes, obesity, and mental disorder), total charges, length of stay, and patient disposition as a function of age and race. A multifaceted approach is used to quantify these relationships. A causal study is performed to explore the effect of various comorbidities on patient outcomes. Least squares regression models are developed to evaluate and compare significant factors that influence total charges and length of stay. Logistic regression is used to study the factors that may cause patient mortality or transferring. In addition, different survival models are developed to study the impact of comorbidity on length of stay with censoring information. This study shows the interactions and relationship among various comorbidities and breast cancer. It shows that certain hypertension may not increase length of stay and total charges; diabetes behaves differently among general population and breast cancer patients; mental disorder has an impact on patient disposition that affects true length of stay and charges, and obesity may have limited effect on patient outcomes. Moreover, this study will help to better understand the expenditure patterns for population subgroups with several chronic conditions and to quantify the impact of comorbidities on patient outcomes. Lastly, it also provides insight for breast cancer patients with comorbidities as a function of age and race.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10729-009-9119-6DOI Listing

Publication Analysis

Top Keywords

breast cancer
24
length stay
24
patient outcomes
20
impact comorbidity
12
cancer patients
12
total charges
12
comorbidity breast
8
patient
8
cancer patient
8
mental disorder
8

Similar Publications

Management of nausea and vomiting induced by antibody-drug conjugates.

Breast Cancer

January 2025

Advanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.

Antibody-drug conjugates (ADCs) are an emerging class of anticancer therapy that combines the specificity and long circulation half-life of monoclonal antibodies with the cytotoxic potency of the payload connected through a chemical linker. The optimal management of toxicities is crucial for improving quality of life in patients undergoing ADCs and for avoiding improper dose reductions or discontinuations. This article focuses on the characteristics and management of nausea and vomiting (NV) induced by three ADCs: trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd).

View Article and Find Full Text PDF

Purpose: Trophoblast cell-surface antigen 2 (Trop2) is overexpressed in various solid tumors and contributes to tumor progression, while its expression remains low in normal tissues. Trop2-targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen. Leveraging the enhanced specificity of ADCs, we conducted the first immunoPET imaging study of Trop2 expression in gastric cancer (GC) and triple-negative breast cancer (TNBC) models using Zr-labeled Trodelvy ([Zr]Zr-DFO-Trodelvy).

View Article and Find Full Text PDF

Background: Breast carcinoma stands out as the most widespread invasive cancer and the top contributor to cancer-related mortality in women. Nanoparticles have emerged as promising tools in cancer detection, diagnosis, and prevention. In this study, the antitumor and apoptotic capability of silver nanoparticles synthesized through Scrophularia striata extract (AgNPs-SSE) was investigated toward breast cancer cells.

View Article and Find Full Text PDF

SHP2 promotes the epithelial-mesenchymal transition in triple negative breast cancer cells by regulating β-catenin.

J Cancer Res Clin Oncol

January 2025

Key Laboratory of Laboratory Medicine, Ministry of Education of China, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.

Purpose: Growing evidence suggests that the tyrosine phosphatase SHP2 is pivotal for tumor progression. Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer, characterized by its high recurrence rate, aggressive metastasis, and resistance to chemotherapy. Understanding the mechanisms of tumorigenesis and the underlying molecular pathways in TNBC could aid in identifying new therapeutic targets.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!